Search Results 1521-1530 of 18962 for Neoplasm

  1. Spinal cord tumor - Doctors and departments - Mayo Clinic

    ... Neoplastic meningitis, Diffuse glioma, Pilocytic astrocytoma, Plexiform neurofibroma, Diffuse midline glioma. Show more areas of focus for Maciej M. Mrugala ...

  2. Spinal cord tumor - Doctors and departments - Mayo Clinic

    ... Neoplastic meningitis, Diffuse glioma, Pilocytic astrocytoma, Plexiform neurofibroma, Diffuse midline glioma. Show more areas of focus for Maciej M. Mrugala ...

  3. Publications - Trenton R. Foster, M.D. - Mayo Clinic

    Oncocytic Adrenal Neoplasms: Clinical Profiles and Long-Term Outcomes. Am Surg. 2025 Mar; 91 (3):381-385 Epub 2024 Oct 21. View PubMed; Aizpuru M, Briggs CM ...

  4. Publications - Nahid Y. Vidal, M.D. - Mayo Clinic

    ChatGPT underperforms in triaging appropriate use of Mohs surgery for cutaneous neoplasms. JAAD Int. 2023 Sep; 12:168-170 Epub 2023 June 09. View PubMed ...

  5. Acoustic neuroma - Doctors and departments - Mayo Clinic

    ... Neoplastic meningitis. Show more areas of focus for Maciej M. Mrugala, M.D., Ph.D. Research. Acoustic neuroma ...

  6. An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer - Mayo Clinic

    Low-risk NMIBC is defined as low-grade lesions or papillary urothelial neoplasms of low malignant potential (PUNLMP; WHO/ISUP 2004 grading system), or TaG1 ...

  7. Mayo Clinic Minute: Pancreatic cancer is the most lethal

    Pancreatic cancer can be a frightening diagnosis. Compared to most other cancers, survival rates are much lower and death often occurs at a more rapid pace.

  8. Publications - Natally Horvat , M.D., Ph.D. - Mayo Clinic

    ... neoplasms for local excision. Tech Coloproctol. 2023 Nov; 27 (11):1047-1056 Epub 2023 Mar 12. View PubMed; Khasawneh H, Ferreira Dalla Pria HR, Miranda J ...

  9. Azacitidine and Sonidegib in Treating Patients With Myeloid Malignancies - Mayo Clinic

    Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm ≤ 14 days prior to registration. Active ...

  10. A Study to Evaluate the Effectiveness, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Participants With Hydroxyurea-Resistant/Intolerant Polycythemia Vera - Mayo Clinic

    Participation eligibility · Meets the criteria for post PV MF as defined by the International Working Group-Myeloproliferative Neoplasms Research and Treatment ( ...